ChrysCapital-backed Indian drug maker Intas Pharmaceuticals is reportedly considering scrapping its public listing amid decade-low IPO valuations in the country due to the fallout from political gridlock.

The buyout firm had approached Goldman Sachs and Temasek about selling a 10.2 per cent stake in case the IPO falls through according to Bloomberg, which cited a person with knowledge of the matter.